# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Bradley Canino maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $120 t...
Wedbush analyst David Nierengarten reiterates Blueprint Medicines (NASDAQ:BPMC) with a Outperform and maintains $110 price t...
HC Wainwright & Co. analyst Andrew Fein reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $125 price...
Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.
JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and maintains $11...
Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:BPMC) with a Buy and maintains $97 price target.
-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term...